Background {#Sec1}
==========

Primary malignant melanoma of the esophagus (PMME) is a rare disease, accounting for 0.1--0.2% of malignant esophageal lesions \[[@CR1]\]. Primary amelanotic malignant melanoma (amelanotic-type) accounts for 10--25% of all PMME, and its prognosis is extremely poor because of its highly malignant biological behavior and delays in the accurate diagnosis \[[@CR2]\]. Although an endoscopic biopsy can aid in the diagnosis of PMME, its accuracy is unsatisfactory, especially for the diagnosis of amelanotic type \[[@CR2]\]. There are few reports of amelanotic type PMME. We herein report an 86-year-old woman with amelanotic-type PMME.

Case presentation {#Sec2}
=================

An 86-year-old woman was admitted to our hospital with symptoms of dysphagia. Upper gastrointestinal endoscopy showed an elevated lesion 33--36 cm from an incisor tooth accompanied by ulcers at the center of lesion, which was located in the lower thoracic esophagus (Fig. [1](#Fig1){ref-type="fig"}a). Another submucosal tumor located at the anal site of the lower thoracic esophagus was considered intramural metastasis. Esophagography showed the main tumor lesion on the left antero-lateral wall of the lower esophagus and a submucosal tumor on the other side causing constriction of the esophagus. The main lesion had good extension on its basal part, indicating that the depth of invasion was the submucosal level (Fig. [1](#Fig1){ref-type="fig"}b). Contrast-enhanced computed tomography (CT) showed the protruded tumor lesion to be 3 cm in size, with no findings of lymph node or distant metastasis (Fig. [1](#Fig1){ref-type="fig"}c). Positron emission tomography-CT (PET-CT) showed an increased uptake of fluorodeoxyglucose (^18^F-FDG) in the lower thoracic esophagus and no findings of lymph metastasis (Fig. [1](#Fig1){ref-type="fig"}d). A blood test showed that tumor markers, such as carcinoembryonic antigen (CEA) and squamous cell carcinoma associated antigen (SCC), were not elevated. A pathological examination of an endoscopic biopsy revealed moderately to poorly differentiated squamous cell carcinoma. Based on these preoperative analyses, the patient was diagnosed with cT2N0M0, cStageII esophageal squamous cell carcinoma.Fig. 1**a** Upper gastrointestinal endoscopy showed a type 1 tumor in the lower thoracic esophagus. **b** Constructed radiography showed the main tumor lesion on the left antero-lateral esophageal wall. **c** Contrast-enhanced CT showed that this tumor lesion measured 3 cm and occupied the esophageal lumen. **d** Positron emission tomography CT showed an uptake in the lower thoracic esophagus and no findings of lymph metastasis

Because the patient was elderly and had a poor performance status (PS 2), she did not undergo preoperative therapy, postoperative therapy, or lymph node dissection of the superior to mid-mediastinum regions. We instead performed thoracoscopy- and laparoscopy-assisted subtotal esophagectomy and reconstruction with the gastric tube. Under thoracoscopy and laparoscopy, we performed subtotal esophagectomy and lymphadenectomy, and reconstruction was performed through the retrosternal route. The total operation time was 377 min, and intraoperative blood loss was 105 ml. Oral diet was started 11 days after the operation, and the patient was transferred to another hospital for rehabilitation on day 25 in a good general condition.

Three tumors were found in the resected specimen; the biggest tumor was 58 × 52 mm in size, and none were stained with Lugol or showed deposition of melanocytes (Fig. [2](#Fig2){ref-type="fig"}a--c). A pathological examination showed that the tumors were located at the mucosa and submucosa of the esophageal wall and were composed of atypical epithelioid cells in a sheeted pattern with necrosis and spindle-shaped cells in a haphazard pattern; however, no melanocytes were observed. Immunohistochemically, atypical epithelioid cells were positive focally for S-100 and HMB45 and partially for Melan-A (Fig. [3](#Fig3){ref-type="fig"}), and spindle-shaped cells were positive focally for these markers. However, all of them were negative for almost all of the epithelial markers. We thus decided on a diagnosis of amelanotic type PMME. Although lymph node metastasis at the paracardial lymph nodes (No. 2) was detected, a CT scan performed at 12 months after surgery showed no findings of recurrence.Fig. 2Macroscopic findings. **a**, **b** There were three tumors at the site of the lower thoracic esophagus and gastroesophageal junction, the biggest tumor of which measured 58 × 52 mm; none were stained with Lugol or showed the deposition of melanocytes. **c** Magnified image of the tumorsFig. 3**a** Histopathological findings at the section, which is located on the yellow line in Fig. [2](#Fig2){ref-type="fig"}c (hematoxylin and eosin staining). The tumors were located at the submucosa and exhibited hyperplasia-like epithelioid cells but no melanocytes. Histopathological findings (immunohistochemical staining). **b** The tumors were diffusely positive for HMB45. **c** The tumors were partially positive for Melan-A

Discussion {#Sec3}
==========

PMME is a rare disease, accounting for 0.5% of all noncutaneous melanomas with an estimated incidence of 0.0036 cases per million/year \[[@CR1], [@CR3]--[@CR5]\]. The prognosis of PMME is extremely poor. In most cases, the patients are usually diagnosed at a late stage, and 30--40% of them have metastases at the same time. Gao reported that the median survival time of patients with PMME is 18.1 months, and the 1- and 5-year survival rates are 51% and 10%, respectively \[[@CR6]\]. Primary amelanotic malignant melanoma, which we experienced in this case, has been reported in only 19 cases from 1996 to 2018 (Table [1](#Tab1){ref-type="table"}) \[[@CR2], [@CR7]--[@CR18]\]. Amelanotic type is especially uncommon among PMME, and its prognosis is also poor.Table 1Search results for case reports of amelanotic malignant melanoma of the esophagus between 1996 and 2018 \[[@CR2], [@CR7]--[@CR18]\]ReferenceAge/sex\
Tumor sizeEndoscopic findingsLocationTNM stagePreoperative diagnosisTreatmentPrognosisLee et al. \[[@CR15]\]47/M 3 cmPolypoid tumorLower esophagusn.a.n.a.SurgeryDied 4 months after surgeryLee et al. \[[@CR15]\]39/F 1.5 cmPolypoid and ulcerated tumorLower esophagusn.a.Poorly-differentiated carcinomaSurgeryNo recurrent 4 months from surgerySuzuki et al. \[[@CR8]\]58/M 6.5 cmUlcerated tumorMiddle esophagusT3N1M0, IIISquamous cell carcinomaSurgery, CT, IT and ETAlive 53 months after surgery(recurrence at 11 months)Heidemann et al. \[[@CR7]\]75/M 8 cmUlcerated tumorMiddle and distal esophagusn.a.n.a.SurgeryRecurrent at 7 monthsStringa et al. \[[@CR10]\]59/M 7.5 cmPolypoid and ulcerated tumorLower third of the esophagusn.a.n.a.SurgeryDisseminated 14 months after surgeryDe Smione et al. \[[@CR9]\]58/F\
3 cmPolypoid tumorMiddle esophaguspT1N0M0, IASquamous cell carcinomaSurgeryDied 16 months after surgeryWang et al. \[[@CR16]\]n.a.\
n.a.n.a.n.a.n.a.n.a.n.a.n.a.Kranzfelder et al. \[[@CR11]\]57/F 7 cmUlcerated tumorDistal esophagusn.a.PMMESurgery and RTDied 4 months after sugeryTerada et al. \[[@CR12]\]87/F n.a.Ulcerated tumorDistal esophagusn.a.n.a.CT and RTDied 12 months after first presentationTerada et al. \[[@CR12]\]56/M n.a.Polypoid tumorMiddle esophagusn.a.n.a.CT and RTDied 7 months after first presentationCarr-Locke et al. \[[@CR18]\]66/F 3.5 cmPolypoid and ulcerated tumordistal esophagusn.a.n.a.SurgeryAlive 2 months after surgeryLohmann et al. \[[@CR13]\]63/M 3.6 cmSessile tumorMiddle esophagusn.a.n.a.Surgery and CTDied 12 months after diagnosisLohmann et al. \[[@CR13]\]67/F [2.2 cm](http://2.2.cm)Polypoid and ulcerated tumorMiddle esophagusn.a.n.a.SurgeryAlive 60 months after surgeryLohmann et al. \[[@CR13]\]72/M n.a.Polypoid tumorMiddle esophagusn.a.n.a.Laser ablationDied 13 months after diagnosisLohmann et al. \[[@CR13]\]70/F 10 cmSessile and ulcerated tumorDistal esophagusn.a.n.a.SurgeryDied 2 months after diagnosisLohmann et al. \[[@CR13]\]58/F 11 cmPolypoid and ulcerated tumorDistal esophagusn.a.n.a.SurgeryDied 4 months after diagnosisRamaswamy et al. \[[@CR17]\]24/F 4.3 cmPolypoid tumorCervical esophagusn.a.n.a.Surgery and CTDied 8 months after first presentationHirayama et al. \[[@CR14]\]77/F 2 cmPolypoid tumorMiddle esophagusn.a.PMMESurgeryNo recurence 3 year after surgeryKobayashi et al. \[[@CR2]\]68/M 2 cmPolypoid tumorMiddle esophagusT1bN0M0, IAMalignant tumorSurgeryNo recurrence 1.5 year after surgeryCurrent case86/F 3 cmPolypoid tumorDistal esophagusT2N0M0, IISquamous cell carcinomaSurgeryNo recurrent finding 12 months from surgeryThis article is included in the review of Bisceglia et al. \[[@CR13]\]. *M* male, *F* female, *n.a*. not available, *CT* chemotherapy, *RT* radiation therapy, *ET* endocrine therapy, *IT* immunotherapy

One of the reasons for the poor prognosis of amelanotic type is the difficulty of making an early, correct diagnosis. Several factors are implicated in this difficulty. First, the diagnostic criteria for PMME are not easy to apply for a preoperative diagnosis. The Diagnostic Criteria for PMME were defined by Allen and Spitz as follows: (i) a typical histological pattern of melanoma, with melanin granules inside the tumor cells, and (ii) an origin in an area of junctional activity in the squamous epithelium. Junctional activity is defined as melanocytic proliferation in the junctional zone between the dermis and epidermis with its derivatives. In other words, the tumor cells are spread horizontally in the basal layer of the esophageal epithelium. These findings and the presence of in situ melanoma without a history of cutaneous melanoma lead to the absolute diagnosis of PMME \[[@CR2], [@CR10], [@CR19], [@CR20]\]. In our case, we recognized junctional activity on surgical specimens but noted no such activity on an endoscopic biopsy sample. It is thus not easy to reach a definitive diagnosis using these criteria because endoscopic biopsy tissue samples tend to be too small to confirm the structure of junctional activity. Second, the findings on an endoscopic examination are not sufficient to make a diagnosis. A black tone is a well-known endoscopic characteristic of PMME, but various other colors, such as purple and brown, are often observed in 10--25% of PMME tumors, depending on the melanin quantity \[[@CR21], [@CR22]\]. Amelanotic type produces no melanin pigments, so a preoperative diagnosis is often difficult. It is important to suspect PMME when a black or brown mass is observed in the esophagus. Finally, a biopsy is limited in its ability to support an accurate diagnosis. While a biopsy can aid in the diagnosis of PMME, its accuracy is only approximately 80%. Furthermore, 20--50% of patients are misdiagnosed with poorly differentiated carcinoma, especially in cases of amelanotic melanoma, because of the marked variability in the histological appearance.

The diagnosis of PMME by an endoscopic biopsy is extremely difficult for the following reasons: some tumors are amelanotic and do not contain melanin granules that are detectable by microscopy; melanocytes tend to concentrate in foci and so may be missed by endoscopic biopsy; and the primary esophageal melanoma is often covered by normal squamous epithelium \[[@CR20], [@CR23]\]. Therefore, immunohistochemistry (IHC) investigations are useful for obtaining an accurate diagnosis.

However, histology and IHC alone have limitations due to the range of differential diagnoses for PMME, especially for tumors with few or no melanin granules. S-100 protein was originally used to diagnose melanoma \[[@CR24]\]. Subsequently, HMB-45 was found to be more specific for melanoma, as it indicated active melanosome formation \[[@CR25]\]. Melan-A is another immunohistochemical marker that was found to be positive in a small percentage of HMB-45-negative melanomas \[[@CR26]\]. In our review of the literature, the rate of positivity with cytokeratin was reported to be 7% \[[@CR27]\]. S-100 therefore seems to be the most sensitive marker for melanoma, while HMB-45 and Melan-A demonstrate relatively good specificity but not as good sensitivity as S-100 \[[@CR28]\]. The combination of these antibodies may improve the accuracy of the diagnosis.

It is therefore important to keep PMME in mind when endoscopy shows an esophageal tumor with uncommon findings, especially a tumor with an uncommon color and conduct comprehensive examinations in order to make an accurate diagnosis.

Despite the poor prognosis, there is no consensus for the standard management of PMME of amelanotic type, because it is a rare disease. Surgery is the most common treatment method for PMME, and the benefits of chemotherapy are unclear. However, some authors have reported the effectiveness of neoadjuvant and adjuvant chemotherapy \[[@CR29]\]. Chemotherapy was also reported to be beneficial for recurrent cases \[[@CR30]\]. Other authors have noted that immune check-point inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies, benefit patients with advanced PMME \[[@CR30], [@CR31]\]. In the accumulated reports, although no significant correlation has been noted between the treatment and prognosis, one patient reported by Suzuki et al. who received neoadjuvant chemotherapy, adjuvant chemotherapy, and immunotherapy after surgery showed a long-term survival \[[@CR8]\]. Adjuvant chemotherapy and immunotherapy may be of benefit to patients with PMME; however, further studies will be needed to prove their efficacies.

Conclusion {#Sec4}
==========

In conclusion, we encountered a case of amelanotic type PMME, and the patient remains alive at 1 year after surgery without relapse. The diagnosis of PMME should be based on a combination of findings from a morphological examination, pathological examination, and immunohistochemistry, as PMME sometimes lacks melanin granules inside the tumor cells. It is important to cite PMME as a differential diagnosis of esophageal tumors when in doubt clinically, as the preoperative accurate diagnosis of PMME is difficult, especially for amelanotic type. Improving the accuracy of the diagnosis will ensure that appropriate treatment is provided for patients with PMME.
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